Treatment of Enterohemorrhagic Escherichia coli–Induced Hemolytic Uremic Syndrome (eHUS)

Reinhard Würzner; Magdalena Riedl; Alejandra Rosales; Dorothea Orth-Höller

doi:10.1055/s-0034-1375298

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2014; 40(04): 508-516
DOI: 10.1055/s-0034-1375298

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Enterohemorrhagic Escherichia coli–Induced Hemolytic Uremic Syndrome (eHUS)

Authors

Reinhard Würzner

¹Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria
Magdalena Riedl

²Department of Pediatrics I, Innsbruck Medical University, Innsbruck, Austria

³Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada

⁴Cell Biology Program, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
Alejandra Rosales

²Department of Pediatrics I, Innsbruck Medical University, Innsbruck, Austria
Dorothea Orth-Höller

¹Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria

Abstract

Treatment of enterohemorrhagic Escherichia coli–induced hemolytic uremic syndrome (eHUS) still mostly relies on supportive intensive care regimens. Antibiotic treatment, as administered to eHUS patients during the 2011 O104:H4 outbreak, may reduce the shedding period, but this may apply only to this particular strain. In any case, there is no evidence for a beneficial use in the diarrheal phase and earlier warnings that antibiotic therapy at this stage may actually increase the likelihood of HUS remain unrefuted. Plasma exchange, a frequently chosen therapy in acute atypical HUS, was not beneficial for the outbreak patients and a prospective study of 274 pediatric eHUS patients even indicates a poorer long-term outcome. As eHUS is a disease where complement plays a pathophysiological role and individual beneficial treatments had been published, eculizumab was broadly administered during the outbreak, in particular to severely ill patients. The equally good outcome of treated versus untreated patients obviously does not allow a clear-cut statement, but rather points toward an advantageous use, at least for the severe cases. Although the role of complement should not be overestimated, the use of a complement blocker—not necessarily being a therapeutic option for uncomplicated eHUS—in severe disease may actually make the difference between favorable or detrimental outcome.

Keywords

hemolytic uremic syndrome - enterohemorrhagic Escherichia coli - complement - Shiga toxin

Full Text

References

References
1 Keir LS, Marks SD, Kim JJ. Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther 2012; 6: 195-208
2 Orth-Höller D, Würzner R. Role of complement in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Sem Thromb Hemost 2014; 40 (4) 503-507
3 Orth D, Würzner R. What makes an enterohemorrhagic Escherichia coli?. Clin Infect Dis 2006; 43 (9) 1168-1169
4 Jenke C, Lindstedt BA, Harmsen D, Karch H, Brandal LT, Mellmann A. Comparison of multilocus variable-number tandem-repeat analysis and multilocus sequence typing for differentiation of hemolytic-uremic syndrome-associated Escherichia coli (HUSEC) collection strains. J Clin Microbiol 2011; 49 (10) 3644-3646
5 Geerdink LM, Westra D, van Wijk JA , et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012; 27 (8) 1283-1291
6 Orth D, Grif K, Zimmerhackl LB, Würzner R. Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans. Expert Rev Anti Infect Ther 2008; 6 (1) 101-108
7 Friedrich AW, Bielaszewska M, Zhang WL , et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 2002; 185 (1) 74-84
8 Orth D, Grif K, Khan AB, Naim A, Dierich MP, Würzner R. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn Microbiol Infect Dis 2007; 59 (3) 235-242
9 Melton-Celsa A, Mohawk K, Teel L, O'Brien A. Pathogenesis of Shiga-toxin producing Escherichia coli . Curr Top Microbiol Immunol 2012; 357: 67-103
10 Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365 (9464) 1073-1086
11 Orth-Höller D, Riedl M, Würzner R. Inhibition of terminal complement activation in severe Shiga toxin-associated HUS - perfect example for a fast track from bench to bedside. EMBO Mol Med 2011; 3 (11) 617-619
12 Trachtman H, Austin C, Lewinski M, Stahl RA. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012; 8 (11) 658-669
13 Frank C, Werber D, Cramer JP , et al; HUS Investigation Team. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365 (19) 1771-1780
14 Bitzan M, Poole R, Mehran M , et al. Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother 2009; 53 (7) 3081-3087
15 Ake JA, Jelacic S, Ciol MA , et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005; 115 (6) e673-e680
16 Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Tatara K. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999; 52 (6) 357-362
17 Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 2002; 288 (8) 996-1001
18 Ichinohe N, Ohara-Nemoto Y, Nemoto TK, Kimura S, Ichinohe S. Effects of fosfomycin on Shiga toxin-producing Escherichia coli: quantification of copy numbers of Shiga toxin-encoding genes and their expression levels using real-time PCR. J Med Microbiol 2009; 58 (Pt 7) 971-973
19 Papan C. Effect of antibiotics on Shiga toxin release of EHEC bacteria—is gentamicin the drug of choice. MD thesis: Innsbruck Medical University; 2010
20 Grif K, Orth D, Würzner R. In vitro effect of exposure of different antibiotics on EHEC strains with various types of Shiga toxin. VTEC2009. P01.5.8 Abstract Book 2009; 105
21 Bielaszewska M, Idelevich EA, Zhang W , et al. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 2012; 56 (6) 3277-3282
22 Corogeanu D, Willmes R, Wolke M, Plum G, Utermöhlen O, Krönke M. Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic E. coli O104:H4 from the 2011 German outbreak. BMC Microbiol 2012; 12: 160
23 Slutsker L, Ries AA, Maloney K, Wells JG, Greene KD, Griffin PM. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis 1998; 177 (4) 962-966
24 Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, Acheson DW. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000; 181 (2) 664-670
25 Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342 (26) 1930-1936
26 Dundas S, Todd WT, Stewart AI, Murdoch PS, Chaudhuri AK, Hutchinson SJ. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001; 33 (7) 923-931
27 Smith KE, Wilker PR, Reiter PL, Hedican EB, Bender JB, Hedberg CW. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J 2012; 31 (1) 37-41
28 Wong CS, Mooney JC, Brandt JR , et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 2012; 55 (1) 33-41
29 Hauswaldt S, Nitschke M, Sayk F, Solbach W, Knobloch JK. Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli. Curr Infect Dis Rep 2013; 15 (1) 4-9
30 Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 53 (2) 259-272
31 Loos S, Ahlenstiel T, Kranz B , et al. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012; 55 (6) 753-759
32 Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36 (6) 673-681
33 Rizzoni G, Claris-Appiani A, Edefonti A , et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988; 112 (2) 284-290
34 Gianviti A, Perna A, Caringella A , et al. Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. Am J Kidney Dis 1993; 22 (2) 264-266
35 Loirat C, Sonsino E, Hinglais N, Jais JP, Landais P, Fermanian J ; The French Society of Paediatric Nephrology. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. Pediatr Nephrol 1988; 2 (3) 279-285
36 Szczepiorkowski ZM, Winters JL, Bandarenko N , et al; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25 (3) 83-177
37 Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 2011; 378 (9796) 1089-1093
38 Greinacher A, Friesecke S, Abel P , et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011; 378 (9797) 1166-1173
39 Menne J, Nitschke M, Stingele R , et al; EHEC-HUS consortium. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345: e4565
40 Rosales A, Hofer J, Zimmerhackl LB , et al; German-Austrian HUS Study Group. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 2012; 54 (10) 1413-1421
41 Orth D, Khan AB, Naim A , et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182 (10) 6394-6400
42 Lapeyraque AL, Malina M, Fremeaux-Bacchi V , et al. Eculizumab in severe Shiga toxin associated HUS. N Engl J Med 2011; 364 (26) 2561-2563
43 Hillmen P, Muus P, Röth A , et al. Long term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013; 162 (1) 62-73
44 Legendre CM, Licht C, Muus P , et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368 (23) 2169-2181
45 Würzner R, Schulze M, Happe L , et al. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm 1991; 8 (5–6) 328-340
46 Evans MJ, Rollins SA, Wolff DW , et al. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol Immunol 1995; 32 (16) 1183-1195
47 Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25 (11) 1256-1264
48 Kielstein JT, Beutel G, Fleig S , et al; Collaborators of the DGfN STEC-HUS registry. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012; 27 (10) 3807-3815
49 Ullrich S, Bremer P, Neumann-Grutzeck C , et al. Symptoms and clinical course of EHEC O104 infection in hospitalized patients: a prospective single center study. PLoS ONE 2013; 8 (2) e55278
50 Romer S, Schaumburg F, Karch H, Schwindt W, Waltenberger J, Lebiedz P. Septic shock and ARDS after Eculizumab application in Shiga-toxin associated HUS during the outbreak of Shiga toxin-producing enterohaemorrhagic E. coli O104:H4. Med Klin 2012; 107 (4) 329-330
51 Delmas Y, Vendrely B, Clouzeau B , et al. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 2014; 29 (3) 565-572
52 Harambat J, De Charette C, Godron A, Bordes C, Delmas Y, Llanas B. Eculizumab in Shiga toxin associated hemolytic uremic syndrome: a single center matched-cohort study. Pediatr Nephrol 2013; 28 (8) 1373
53 Gitiaux C, Krug P, Grevent D , et al. Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol 2013; 55 (8) 758-765
54 Dhawan V, Ariyamuthu V, Malhotra K, Bichu P. Renal recovery in a child with D+HUS. Is eculizumab a typical drug?. Am J Kidney Dis 2013; 61 (4) B37
55 Preußel K, Höhle M, Stark K, Werber D. Shiga toxin-producing Escherichia coli O157 is more likely to lead to hospitalization and death than non-O157 serogroups—except O104. PLoS ONE 2013; 8 (11) e78180
56 Thurman JM, Marians R, Emlen W , et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4 (12) 1920-1924
57 Morigi M, Galbusera M, Gastoldi S , et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187 (1) 172-180
58 Rittirsch D, Redl H, Huber-Lang M. Role of complement in multiorgan failure. Clin Dev Immunol 2012; 2012: 962927
59 Würzner R, Orren A, Lachmann PJ. Inherited deficiencies of the terminal components of human complement. Immunodefic Rev 1992; 3 (2) 123-147
60 Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007; 25 (11) 1265-1275
61 German Society of Nephrology. Advice on the use of eculizumab during the 2011 EHEC HUS outbreak, 04.06.2011. Available at: http://www.dgfn.eu/fileadmin/migrated/content_uploads/Advice_of_DGfN_on_the_use_of_eculizumab_in_EHEC_HUS_outbreak_20110604.pdf. Accessed April 29, 2014 2011
62 Nitschke M, Sayk F, Härtel C , et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 2012; 307 (10) 1046-1052
63 Vonberg RP, Höhle M, Aepfelbacher M , et al. Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study. Clin Infect Dis 2013; 56 (8) 1132-1140
64 Martin DL, MacDonald KL, White KE, Soler JT, Osterholm MT. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med 1990; 323 (17) 1161-1167